Durvalumab + Olaparib
Phase 2Terminated 1 views this week 0 watching💤 Quiet
Interest: 27/100
27
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Biochemically Recurrent Prostate Carcinoma
Conditions
Biochemically Recurrent Prostate Carcinoma, Prostate Adenocarcinoma
Trial Timeline
Apr 13, 2021 → Jun 6, 2025
NCT ID
NCT04336943About Durvalumab + Olaparib
Durvalumab + Olaparib is a phase 2 stage product being developed by AstraZeneca for Biochemically Recurrent Prostate Carcinoma. The current trial status is terminated. This product is registered under clinical trial identifier NCT04336943. Target conditions include Biochemically Recurrent Prostate Carcinoma, Prostate Adenocarcinoma.
What happened to similar drugs?
0 of 1 similar drugs in Biochemically Recurrent Prostate Carcinoma were approved
Approved (0) Terminated (0) Active (1)
Hype Score Breakdown
Clinical
12
Activity
0
Company
15
Novelty
0
Community
0
Clinical Trials (4)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06419179 | Phase 2 | Recruiting |
| NCT06441747 | Phase 2 | Recruiting |
| NCT04336943 | Phase 2 | Terminated |
| NCT03534492 | Phase 2 | Completed |
Competing Products
2 competing products in Biochemically Recurrent Prostate Carcinoma
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Darolutamide (BAY1841788, Nubeqa) | Bayer | Phase 3 | 41 |
| Darolutamide(BAY1841788, Nubeqa) + Enzalutamide | Bayer | Phase 2 | 32 |